For research use only. Not for therapeutic Use.
Momelotinib dihydrochloride (CAS 1380317-28-1) is a pharmacological compound under investigation for its potential in the treatment of myeloproliferative neoplasms, particularly myelofibrosis. As a Janus kinase (JAK) inhibitor, Momelotinib dihydrochloride interferes with signaling pathways involved in hematopoiesis and inflammatory processes. By targeting JAK1 and JAK2, it may help manage the symptoms associated with myelofibrosis, such as splenomegaly and anemia.
| Catalog Number | I048007 |
| CAS Number | 1380317-28-1 |
| Synonyms | CYT387 dihydrochloride |
| Molecular Formula | C23H24Cl2N6O2 |
| Purity | 98% |
| Target | JAK1、JAK2与ALK2 |
| Target Protein | IPNATXQRPWRHKD-UHFFFAOYSA-N |
| Appearance | Solid |
| IC50 | JAK1 ([IC50]=11 nM), JAK2 (IC50=18 nM), JAK3 (IC50=155 nM) and TYK2 (IC50=17 nM) |
| IUPAC Name | N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide;dihydrochloride |
| InChI | InChI=1S/C23H22N6O2.2ClH/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;;/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);2*1H |
| InChIKey | IPNATXQRPWRHKD-UHFFFAOYSA-N |
| SMILES | C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N.Cl.Cl |
